MicroRNAs (miRNAs), B22-nt RNAs that mediate post-transcriptional regulation of mRNAs in animals and plants, are a diverse class of regulatory genes whose specific biological functions are largely unknown. Here we detail a protocol to design and introduce into cultured Drosophila and human cells sequence-specific antisense oligonucleotides (ASOs) that block the function of individual miRNAs. Coupled with recent studies that catalog the miRNAs expressed in diverse cultured cells, our method offers a rapid (o1 week) approach to validate miRNA targets and to study the cellular functions of individual human and Drosophila miRNAs. ASO-based inactivation of miRNAs is faster and simpler than comparable genetic or 'sponge'-based approaches, for which extensive recombinant DNA manipulation is required. We present our ASO design principles and an optimized transfection protocol in which transfection efficiency of Drosophila Schneider 2 cells can approach 100%. Our 3¢-cholesterol-modified ASOs have enhanced potency, allowing miRNA inhibition for at least 7 d from a single transfection.
INTRODUCTION
MicroRNAs are an ancient class of B22-nt small silencing RNAs that mediate post-transcriptional regulation of mRNAs in animals and plants. When bound to partially complementary sequences in their target mRNAs, animal miRNAs tune gene expression by repressing translation or accelerating mRNA decay [1] [2] [3] [4] [5] . This regulation is critical for diverse biological processes, including stem cell maintenance, musculoskeletal, circulatory and nervous system development, insulin secretion and oncogenic transformation [6] [7] [8] [9] [10] [11] [12] . More than 1,000 miRNA genes have now been identified in animals, of which a large fraction is conserved between vertebrates and invertebrates. However, few specific functions have been described for individual miRNAs.
To accelerate the study of miRNA function and mechanism, we developed a method to disrupt individual miRNAs using ASOs in human tissue culture cells 13 and adapted it for use in Drosophila S2 cells 14 . ASOs bind complementary miRNAs and selectively block silencing in cell extracts, in cultured cells, and in vivo in worms, flies, mice and primates 13, [15] [16] [17] [18] [19] [20] [21] [22] . Studying miRNA function using classical genetic approaches is challenging, as miRNAs often form multigene families with common mRNAs targets, reside in introns of proteincoding genes or derive from polycistronic noncoding transcripts [23] [24] [25] [26] [27] [28] [29] . ASOs can be designed to inactivate a specific miRNA and its paralogs knowing only the sequences of the mature miRNAs. Recent studies cataloging miRNA sequences and expression profiles in flies, worms, mice, humans and cultured cells provide a road map for the use of ASOs to study miRNA targets and the biological pathways they regulate [30] [31] [32] [33] [34] [35] . Here we describe the principles used in our laboratory to design ASO miRNA inhibitors and provide protocols for the efficient delivery of ASO inhibitors into cultured Drosophila Schneider 2 (S2) and human cells.
MicroRNAs and their targets
MicroRNAs are transcribed as hairpin precursors, then sequentially processed by the RNase III enzymes, Drosha and Dicer, to yield double-stranded intermediates bearing 2-nt, 3¢-overhanging ends [36] [37] [38] [39] . These imperfectly paired duplexes are then assembled into long-lived, cytoplasmic protein-RNA complexes called RISCs (RNA-induced silencing complexes) that mediate RNA silencing. Every RISC contains a single-stranded small RNA guide bound to a member of the Argonaute family of proteins 40, 41 . The miRNA and Argonaute protein act together to bind and silence target mRNAs (Fig. 1) . Perfectly complementary targets are efficiently silenced by the endonucleolytic cleavage activity of some Argonaute proteins [41] [42] [43] , but the vast majority of predicted targets in animals are only partially paired 31, [44] [45] [46] [47] [48] [49] and likely cannot be cleaved 50 . Instead, they bind RISC using the 'seed' of the miRNA, nucleotides 2-7, and are translationally repressed and/or degraded by a pathway distinct from the endonucleolytic activity of RISC 48, 51, 52 .
The remarkably small number of nucleotides required for miRNA-directed target repression suggests that each miRNA may regulate hundreds of mRNA species 31, [44] [45] [46] [47] [48] [49] . Experimentally validating computationally predicted miRNA targets and proving the biological significance of each mRNA candidate remains a daunting challenge. Selective inactivation of miRNAs with ASOs has already helped in accelerating this task.
Selection of ASO chemistry miRNA activity has been blocked effectively using ASOs containing several distinct nucleic acid modifications. In general, an effective ASO is (i) resistant to nonspecific cellular ribonucleases, (ii) resistant to miRNA-directed cleavage by RISC and (iii) binds miRNAs in RISCs with high affinity, effectively out-competing binding to target mRNAs. We designed ASO inhibitors containing exclusively 2¢-Omethyl (2¢-O-Me) ribose sugars (Fig. 2) . 2¢-O-Me oligonucleotides are resistant to cleavage by both RISC and other cellular ribonucleases 13, 18, 53 . Moreover, 2¢-O-methyl-modified RNA-RNA hybrids are more thermodynamically stable than either RNA-RNA or DNA-RNA duplexes 53, 54 . Other base modifications with enhanced hybridization stability have also been used successfully to inhibit miRNA function, including ASOs combining 2¢-deoxy and locked nucleic acid (LNA) nucleotides [55] [56] [57] [58] , 2¢-O-methyl and LNA 59 , all 2¢-O-methoxyethyl ASOs and ASOs incorporating pyrimidines bearing 2¢-O-fluoro modifications 19, 20 . 2¢-O-methoxyethyl-modified oligonucleotides are not available commercially. Nuclease-resistant phosphorothioate backbone linkages, in combination with ribose modifications, have also been employed in cultured cells and in vivo in mice and nonhuman primates 16, 19, 20, 22, 60 (Fig. 2) . miRNA inhibition by peptide nucleic acid oligonucleotides has been reported for cultured cells 59 .
A 3¢-terminal cholesterol group appears to aid delivery of ASOs to cells. Originally used to enhance delivery of ASOs targeting mRNAs [61] [62] [63] , cholesterol modification has been adapted to deliver both small interfering RNAs and miRNA-blocking ASOs to the liver and other tissues in mice 16, 64 . We find that 3¢-conjugation of cholesterol to ASOs makes them B8-fold more potent when transfected into S2 cells 14 (see Supplementary Data 1 and Supplementary Fig. 1 online) . Cholesterol conjugation likely aids ASO delivery into cells; however, it may have properties that further enhance ASO activity, such as improved intracellular escape from liposomes, relocalization of the targeted miRNAs or enhancement of ASO stability. Recent studies in mice support such ideas 60 .
Does length really matter?
To make the ASO more 'target-like' , we added five extra nucleotides to each of its ends, for a total of 31 nucleotides 13 
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A*U*U*U*A*C*G*U*G*A*U*A*G*A*C*C*A*U*G*C*U*G*U 5′ and in fly embryos 17, 18, 20 . Esau and coworkers 20 reported no significant difference between 21 nt and longer ASOs in HeLa cells, but Hutvágner et al. 13 found that 21-mer ASOs were measurably less potent. Similarly, Berger et al. 65 observed only partial inhibition of miR-2 in Drosophila S2 cell reporter assays using a 21-mer ASO. Vermeulen et al. 66 found that increasing ASO length by adding as many as 16 nt to each side of the miRNA-complementary core increased ASO potency as much as tenfold. Consistent with these observations, Ameres and colleagues recently described a sequence-independent, single-stranded RNA-binding activity associated with human RISC 67 . Nonsequence-specific binding by RISC of ASO sequence flanking the miRNA-complementary core may account for the enhanced potency of ASOs longer than 21 nt. These additional ASO sequences might also protect the core from cellular exonucleases. Krutzfeldt 60 suggests this possibility to explain a 'tendency' toward improved disruption of miR-122 in vivo when they extend the ASO by only 1 base on each end. Interestingly, Vermeulen et al. 66 observed that addition of double-stranded, 8-base-pair hairpins to the ends of the ASO increased its potency more than the addition of 16 single-stranded nucleotides. Double-stranded ends may protect the ASO from exonucleolytic destruction or the terminal hairpins may participate in coaxial stacking interactions with the ASO-miRNA duplex, increasing its thermodynamic stability 68 . Supporting the idea that ASOs must have high thermodynamic stability, Elmen et al. 22, 58 recently showed that full complementarity of an ASO is not required if a very high affinity 16-mer LNA targeting the 5¢-end of the miRNA is used. In our experience, 21-nt LNA-substituted ASOs and 31-mer 2¢-O-Me ASOs performed similarly in S2 cells (M.D.H. and P.D.Z., unpublished data). Although the higher affinity of LNAs may permit design of shorter effective ASO inhibitors, we believe that the bulk of published data suggests that the addition of single-or double-stranded sequences flanking the 21 ASO nucleotides complementary to the targeted miRNA potentiates miRNA inhibition by 2¢-O-Me ASOs.
The mechanism of miRNA inhibition The mechanism by which ASOs block miRNA function remains controversial. Initial studies suggested that ASOs block miRNA function by binding mature miRNAs in RISCs. 31-mer 2¢-O-Me ASOs act as stoichiometric inhibitors in vitro and in HeLa cells and bind miRNAs in RISCs in vivo in Caenorhabditis elegans 13 . Unexpectedly, ASO-targeted miRNAs could not be detected by northern hybridization in mice that were injected with 'antagomirs' , cholesterol-modified 2¢-O-Me ASOs with terminal phosphorothioate modifications ( Fig. 2) 16, 60 . Similarly, Esau and coworkers 20 found that fully modified 2¢-O-methoxyethyl phosphorothioate ASOs targeting the same miRNA, miR-122, induced the apparent destruction of the miRNA. Potentially, the phosphorothioate modification used in these studies triggered miRNA degradation. Chan et al. 55 also report that 2¢-O-methyl or LNA/DNA ASOs bearing phosphodiester backbones reduced apparent miRNA levels, but these authors suggest that standard northern hybridization probes may be unable to disrupt the high affinity of miRNA-ASO duplexes, even under denaturing conditions.
If high-affinity ASO-miRNA duplexes block access of standard DNA oligonucleotide northern probes, higher-affinity LNA probes coupled with an increased hybridization temperature might enhance detection of a miRNA that is tightly bound to an ASO rather than degraded. Indeed, we found that an LNA probe and higher hybridization temperature enhanced detection of synthetic let-7 incubated with B1,000-fold excess antagomir (Supplementary Fig. 2a online) . Similarly, endogenous miR-277 was undetectable by northern blot in miR-277 LNA ASO-treated Drosophila S2 cells if a DNA probe was used, but miR-277 was detected with an LNA probe and higher hybridization temperature. Interestingly, miR-277 2¢-O-Me ASOs had no significant effect on miR-277 levels using DNA or LNA probes. These data suggest that in Drosophila cells, ASOs do not promote miRNA degradation and that, in some cases, ASOs can interfere with miRNA detection by northern blot with DNA probes (see Supplementary Data 2 online).
Alternatives to ASOs for studying miRNA function A number of alternative approaches are available to study the loss of function of specific miRNA genes.
Gene targeting using homologous recombination is possible in mice and flies 69, 70 and has revealed roles for individual miRNAs in the mouse immune system 71 and heart 9 , and in the development of fly muscle 8 and sensory organs 72 . Although roles for miRNAs in development have been suggested by the analysis of fly embryos injected with 2¢-O-Me ASOs 17 or developing zebrafish injected with pre-miRNA-complementary 'morpholinos' (B25-nt oligonucleotides containing 6-carbon morpholine rings and a phophoramadite backbone instead of ribose sugars and a phosphodiester backbone) 73 , ASOs have yet to be utilized in developing mice. Thus, targeted deletion is currently the only way to study loss of miRNA function in mouse development.
Gene targeting is also possible in human and mouse tissue culture cells 74 . Only a single study to date has used this approach 75 , likely because gene targeting in somatic cells is technically challenging and laborious, requiring construction of a targeting vector, recombination selection schemes that can vary widely in efficiency depending on the gene to be targeted and screening to verify genotype. Moreover, the results obtained by somatic gene targeting closely mirror those from parallel experiments using ASOs (see ANTICIPATED RESULTS for more discussion).
A 'knock-out' phenotype in an intact animal is, of course, the most convincing proof of the biological function of an miRNA. Often, however, no observable phenotype results from miRNA loss of function. In a recent study in which deletions were reported for 83% of known miRNA genes in C. elegans, loss of most individual miRNA genes caused no obvious phenotype 76 . Functional redundancy likely explains this result, as combining deletions of several let-7 family members that alone had no phenotype caused distinct phenotypes 25 . In mice, deletion of the miR-17B92 cluster produced dramatic defects in heart, lung and B-cell development, accompanied by inappropriate apoptosis, but deletion of two other paralogs (miR-106aB363 and miR-106bB25) produced no obvious phenotype 77 . Still, it is unclear if one or all of the six miRNAs in the cluster contribute to the observed phenotype. Highlighting the utility of ASOs as an adjunct for rapid functional studies of individual miRNAs, Matsubara et al. 78 had already found that lung cancer cell lines expressing the miR-17B92 cluster undergo apoptosis when miR-17 or miR-20a are inhibited with ASOs. Thus, although gene deletion remains the biological gold standard, its technical difficulty paired with the complex organization of miRNA genes makes it a high-risk, time-consuming approach. 'miRNA sponges' offer a new alternative to inhibit miRNA function that may be superior for inhibiting whole miRNA families. Sponges are highly expressed transgenes bearing multiple, bulged (i.e., noncleavable) miRNA-binding sites complementary to an miRNA of interest. These abundant RNAs compete with endogenous targets and thus 'soak up' RISCs 79 . miRNA sponges have been transfected into tissue culture cells and appear to be as effective as ASOs. Ebert et al. 79 observed that sponges can inhibit miRNAs whose only shared sequence is their seed. This should be considered when targeting a single miRNA that is part of a familysponges may not distinguish among family members, whereas ASOs appear to selectively silence family members that differ by fewer than two bases 80 . In theory, miRNA sponges could be used to make transgenic animals, but to date they have been tested only in cultured cells. Limitations of sponges, compared with ASOs, include (i) the time needed to design, build and test the recombinant sponge vectors, (ii) the reliance on plasmid DNA transfection, which is less efficient than oligonucleotide transfection, and (iii) their inability to selectivity target a single member of an miRNA family.
Transfected siRNAs directed against pre-miRNA loop regions have been reported to decrease miRNA abundance in human tissue culture cells 81, 82 . This method should be used with caution as it appears to be comparatively inefficient, reducing the level of a mature miRNA B80% at best, with the remaining 20% free to interact with targets. A number of issues likely account for the relative inefficiency of siRNA-directed depletion of miRNAs, including the secondary structure of pre-miRNAs, which likely limits access to RISCs. Secondary structure surrounding target sites is a well-documented antideterminant for RNAi 67, 83 . An siRNA targeting a pre-miRNA must also be able to cleave the pre-miRNA before Dicer converts it to a mature miRNA. To date, no evidence suggests that RISC has a kinetic advantage over Dicer. Additionally, miRNA depletion by pre-miRNA-directed siRNAs is limited by mature miRNA turnover. In contrast, ASOs directly inhibit mature miRNAs in RISCs. Because RISC-bound miRNAs may be quite stable, this is an important consideration.
Advantages and limitations of miRNA inhibition by ASOs
In principle, transfected ASOs can be used to study the loss-offunction phenotype for any miRNA expressed in cultured cells by measuring growth rate, induction of apoptosis or changes in mRNA or protein abundance. Derepression of miRNA-regulated genes in the presence of an ASO is especially convincing evidence for a proposed miRNA-target interaction. In contrast to target validation approaches that use cloned 3¢-untranslated region (UTR) reporters and overexpress miRNAs, ASO approaches can demonstrate that an endogenous miRNA interacts with an endogenous target mRNA.
To study miRNA function in human somatic cells, where genetic knockouts are difficult at best, ASO transfection is an essential tool. Studies using cell lines are, of course, limited by the repertoire of miRNAs expressed and by the cellular processes that can be recapitulated in immortalized or transformed cells. To study the role of miRNAs in complex developmental or physiological processes involving the interaction of multiple cell types, the use of model organisms in which miRNAs can be inactivated in vivo with ASOs or by targeted deletions (see above) may be preferable. However, even when studying miRNA function in vivo, validation of miRNA-target regulation in cell lines has the advantage that all the cells studied are essentially identical.
The main technical limitations to the use of ASOs are their delivery, duration of action and specificity. Delivery and duration of action can be assessed using miRNA sensors, genes engineered to place a reporter, such as green fluorescent protein (GFP) or luciferase, under the control of the miRNA of interest (see Experimental design and ANTICIPATED RESULTS). Using the protocol described below, transfection is efficient (490%) and miRNA inhibition is long lasting (47 d). ASOs likely do not discriminate among miRNAs that differ by a single nucleotide. This can be a limitation or an advantage. Because many miRNAs are members of highly related families, i.e., they contain identical seeds, a single ASO likely blocks the function of more than one miRNA in a family. However, a single ASO may not strongly inhibit miRNAs whose only common sequence is the seed 19, 79 . For such applications, cotransfection of multiple ASOs targeting various isoforms is possible 75 . In this respect, genetic approaches are superior for studying individual miRNA family members, whereas miRNA sponges or multiple ASOs are appropriate for studying miRNA families whose members only contain a common seed sequence; single ASO studies may simplify the study of nearly identical miRNA paralogs.
Combinations of ASOs targeting unrelated miRNAs have also been used to disrupt more than one miRNA in the same transfected cells, obviating the need to make and combine multiple genetic knockouts. Because combinatorial control of targets by miRNAs may be common 84 , this approach may prove particularly important for uncovering networks of miRNAs that act together. Vermeulen et al. 66 showed that cotransfection of a six-ASO mixture can effectively derepress reporters for each individual miRNA. Functional studies also suggest that cotransfection of ASOs is effective. For instance, Pedersen et al. 85 asked if five interferon-b induced miRNAs with seed matches to Hepatitis C genes had antiviral effects; indeed, simultaneous cotransfection of all five ASOs, but not controls, significantly enhanced Hepatitis C RNA production.
Experimental design
Control experiments are required to ensure that miRNAs are indeed inactivated by the transfected ASOs. All experiments should employ a miRNA-specific ASO and a mismatched or unrelated control ASO. Suitable controls include the following: compared with control genes. miRNA reporter or 'sensor' constructs typically place one or two perfectly complementary miRNA sites in the 3¢-UTR of reporter gene. In mammalian cells, we use a dual luciferase reporter system in which Photinus pyralis luciferase containing a perfectly paired 3¢-UTR miRNA site is cotransfected with an unregulated Renilla Reniformis luciferase control gene (or vice versa). The relative expression of these two enzymes can be easily quantified by measuring luminescence activity 13 (Box 1, Fig. 3) .
In Drosophila S2 cells, we typically use stably integrated GFP sensor reporters and derive clonal cell lines 14 . Changes in GFP expression are measured by flow cytometry (fluorescence-activated cell sorting; FACS). An advantage of this approach is that transfection efficiency can be assessed by observing the fraction of cells that has increased GFP levels after ASO transfection (Fig. 4) .
After miRNA inhibition is established, any number of functional assays can be performed in the absence of reporters. Examples are discussed in ANTICIPATED RESULTS.
Gain-of-function studies can also be conducted to complement ASO loss-of-function studies. The finding that introduction of an miRNA into cultured cells has the opposite effect of ASO inhibition on an mRNA provides strong support for a regulatory relationship between the miRNA and the mRNA target. Importantly, it also 
BOX 1 | ASSESSING miRNA INHIBITION WITH THE DUAL LUCIFERASE ASSAY
The dual luciferase system offers a relatively simple approach to assess miRNA inhibition. The psiCheck2 vector system from Promega is a commercially available vector that encodes both Photinus pyralis and Renilla Reniformis luciferase genes on a single plasmid with a multiple cloning site in the 3¢-UTR of Renilla luciferase for insertion of synthetic oligonucleotides encoding the miRNA target sites (or other cloned regulatory sequences, such as target 3¢-UTRs). We have not tested this system in S2 cells, but its use has been previously reported 28 . Here we briefly list the steps necessary to adapt this reporter system for miRNA sensing and assessment of miRNA inhibition in cultured cells. Additional information is available from the manufacturer (Dual luciferase Assay Manual: http://www.promega.com/tbs/tm040/tm040.pdf): (i) Design an miRNA target site insert. Design a set of two oligonucleotides corresponding to two tandem copies of the miRNA of interest and its reverse complement. Add appropriate overhanging bases corresponding to the restriction enzyme(s) used to digest the psiCheck vector such that the mature miRNA's reverse complement is in the 5¢-to 3¢-orientation (see manufacturer's information for restriction map; www.promega.com/tbs/tb329/tb329.pdf). XhoI and NotI sites are convenient for directional cloning of inserts (Fig. 3) .
(ii) Clone the miRNA site insert into psiCheck 2 Vector. Digest psiCheck 2 vector, ligate miRNA site insert, transform into E. coli and sequence the insert using a custom sequencing primer to confirm correct orientation of insert (Vector sequence is available in GenBank, accession number AY535007). (vi) Assessing miRNA inhibition. The relative levels of Renilla luciferase should reveal first whether the vector was regulated by the endogenous miRNA and second whether the ASO blocked this regulation. In control ASO-treated cells, the endogenous miRNA should only regulate psiCheck2 + miR, giving it lower Renilla luciferase levels than psiCheck2. However, when the miRNA is inhibited in miRNA ASO-treated cells, Renilla luciferase levels should be similar in all samples. If they are not, miRNA silencing was not fully blocked. ? TROUBLESHOOTING
TIMING
Step (i): 10 min
Step (ii): 3-5 d
Step (iii): 3-5 d
Step ( reduces the likelihood that a cellular phenotype observed with an ASO is due to a nonspecific effect. miRNAs can be introduced using a pri-miRNA expression plasmid 14, [86] [87] [88] , an siRNA whose sequence corresponds to an miRNA 3,89 or a synthetic pre-miRNA 90 . For instance, we used a pri-miR-277 expression vector to augment miR-277 levels and thus increase silencing of GFP reporters responsive to this miRNA 14 . Pedersen et al. 85 complemented their ASO loss-of-function studies (see above) with a gain-of-function study in which they transfected a mix of 5 miRNA-like siRNAs into cultured cells and found that Hepatitis C virus replication was reduced, even in the absence of interferon-b induction. or equivalent REAGENT SETUP ASO stock solution Dilute antisense oligo to 100 mM with sterile dH 2 O. To be certain that the concentration is correct, we check the stock concentration by measuring its absorbance at 260 nM using a spectrophotometer. Extinction coefficients and molecular weights are usually provided with the oligo. 2¢-O-Me oligonucleotides do not require deprotection. For pipetting accuracy, it may also be necessary to make a 10-mM stock, especially when transfecting a single well or very small wells with an ASO. ASO stock solutions can be stored for short term (o1 month) at À20 1C and for long term at À80 1C. S2 + FBS media Combine Schneider's media with one-tenth volume of FBS. Warm to room temperature (B23 1C) before use. Store at 4 1C for up to one month. S2 media Schneider's Drosophila medium (no serum) used for transfection mixes. Warm to room temperature before use. Store at 4 1C for up to one month. DMEM + FBS media Combine DMEM with one-tenth volume of FBS. Warm to 37 1C before use. Store media at 4 1C for up to one month. DMEM DMEM (no serum) used for transfection should be warmed to room temperature. Trypsin-EDTA Prewarm trypsin-EDTA solution to 37 1C. PBS Prewarm Dulbecco's PBS solution to 37 1C.
MATERIALS

PROCEDURE
Design of ASOs to disrupt miRNA function TIMING B1 h 1| Retrieve the sequence of the miRNA(s) of interest from miRBase (http://microrna.sanger.ac.uk/sequences/) 91 .
2| Record the reverse complement of the miR strand sequence.
3| Add five arbitrary bases to both the 5¢-and 3¢-ends of the antisense miR sequence. Our inhibitors have used the sequence 5¢-UCUUA-antisense miRNA-ACCUU-3¢.
4| Check the full-length sequence for potential secondary structure using mFold: http://mfold.bioinfo.rpi.edu/cgi-bin/ rna-form1-2.3.cgi (ref. 92 ). We use the default settings. 5| If the flanking sequences are predicted to be involved in the formation of strong secondary structure elements (DG 4 user defined cutoff value), alter the flanking sequence base composition and repeat Step 4.
6| Perform a BLAST (Basic Local Alignment Search Tool) search using the full-length oligonucleotide. If fortuitous stable base pairing to an mRNA is predicted involving the flanking sequences and 13 or more bases within the targeting sequence, repeat Steps 3-6.
7| Design a control oligo (see Experimental design for a discussion of appropriate controls). Flanking sequences can be identical to those in the experimental ASO. All control oligos should also be checked for strong secondary structure or unintended complementarity to mRNAs as detailed in Steps 4-6. Strong secondary structure elements in any part of the sequence should be minimized by altering that part of the sequence.
8| Order 2¢-O-Me-modified oligonucleotides (Dharmacon, Sigma or many other oligo synthesis vendors). We find that 3¢-conjugation of cholesterol enhances the potency of miRNA inhibition in Drosophila S2 cells ( Supplementary Fig. 3a online) . We order custom cholesterol-conjugated oligonucleotides from Dharmacon using the custom RNA module (http://www.dharmacon.com/rna/rna.aspx).
? TROUBLESHOOTING Cell culture, transfection and analysis of inhibition 9| If using Drosophila S2 cells to study miRNA function, follow option A. If using mammalian cells, follow option B; in our lab, this strategy has been used successfully to transfect both HeLa and NTera2 cells. These transfection protocols can be adapted for RNAi using siRNA or dsRNA by altering only a few steps, as outlined in Box 2. The main PROCEDURE can be adapted for RNAi using siRNA and dsRNA with just a few alterations, as detailed below. In our experience, transfection of dsRNA into Drosophila S2 cells is far more effective than soaking 103 , and dsRNA transfection is more effective than siRNA transfection in S2 cells (M.D.H., unpublished data). For Drosophila S2 cells:
Step 9A(iv): instead of ASO, use 10 pmol of siRNA or 1 mg of dsRNA per well of a 24-well plate (scaled linearly for other volumes).
Step 9A(ix): allow S2 cells to grow for 5 d, and then check protein or mRNA abundance. In our experience, the best knockdown is achieved if a second transfection is performed at day 5. The cells are analyzed on day 10.
For mammalian cells:
Step 9B(v): instead of ASO, use 10 pmol of siRNA per well of a 24-well plate (scaled linearly for other volumes).
Step 9B(x): for mammalian cells, reduction of protein from the gene targeted by the siRNA can usually be achieved after 3-4 d. A second transfection can be performed if knockdown is insufficient, e.g., if the protein half-life is long.
TIMING siRNA or dsRNA transfection of Drosophila S2 cells
Step 9A(iv): 5 min
Step 9A(ix): 5-10 d siRNA transfection of mammalian cells
Step 9B(iv): 5 min
Step 9B(ix): 3-8 d
BOX 3 | ANALYSIS OF CELL NUMBER AND VIABILITY
(i) To dislodge S2 cells, pipette media across the bottom of the well or plate several times. S2 cells are semi-adherent and form loose clumps at low density. As the cells approach the correct density, they become less adherent and the clumps disperse.
(ii) Remove 50 ml of freshly dislodged cells and mix with 50 ml of Trypan blue solution in a 1.5-ml Eppendorf tube. Wait for 3 min.
(iii) Add B20 ml of the cell suspension to the hemocytometer slide. 
TIMING
Steps (i-vi): 5-10 min stock, up to 2 weeks of growth may be necessary to reach 490% viability. Cells can be propagated in one well of a 6-well plate with 2 ml of total volume per well. m CRITICAL STEP Having S2 cells at high density before transfection is important because at lower densities, S2 cells form clumps that may limit transfection efficiency. As the cells reach high density, these clumps disperse. (ii) In a laminar flow hood, dilute cells from a density of 8-10 Â 10 6 cells ml À1 to a density of 2.75 Â 10 5 cells ml À1 with S2 + FBS media. Cells can be removed from the 6-well plate and diluted in a 50-ml conical tube, and then dispensed into the desired dishes. m CRITICAL STEP Diluting the cells to this density is very important. Transfection of too few cells will result in cell death. Transfection of too many cells will cause uptake of the ASO to be inefficient (see Fig. 4 ). (iii) For a 24-well plate, add 450 ml of diluted cells per well (i.e., 90% of the 500-ml final volume per well) and place the plate in the 25 1C incubator. For other types of plates or dishes, all the transfection mixes can be scaled linearly. See Table 1 . Schneider media 24-well plate 450 ml per well 1.25 ml 2 3 . 7 5 ml 1 ml 2 4 ml 6-well plate 1.8 ml per well 5 ml 9 5 ml 4 ml 9 4 ml 10-cm dish 9 ml per dish 25 ml 4 7 5 ml 2 0 ml 4 8 0 ml (ii) Twenty-four hours before transfection, treat cells with trypsin-EDTA and split cells (Box 4) into a 6-well plate so that they will be 30-40% confluent at the time of transfection (B2 Â 10 5 cells per well in 2 ml of DMEM + FBS in one well of a 6-well plate). For other types of plates or dishes, cell and transfection mixes can be scaled linearly. See Table 2 ? TROUBLESHOOTING Troubleshooting advice can be found in Table 3 . 1.8 ml per well 5 ml 9 5 ml 4 ml 9 4 ml 10-cm dish 9 ml per dish 25 ml 4 7 5 ml 2 0 ml 4 8 0 ml 
BOX 4 | SPLITTING ADHERENT MAMMALIAN CELLS
ANTICIPATED RESULTS
Reporter assays
In a typical experiment, a reporter mRNA is used to detect the activity of a specific endogenous miRNA and an ASO is used to inhibit that miRNA. In our experience, inhibiting an miRNA with an ASO typically produces a three-to fivefold increase in reporter protein expression when the reporter mRNA contains perfect target sites that can be cleaved by RISCs (Fig. 4) . miR-277, an miRNA that is expressed in Drosophila S2 cells, does not regulate a GFP reporter lacking target sites. Control and miR-277 ASOs did not change the levels of the nontargeted reporter, ruling out any nonspecific effects of the ASOs on the reporter. When two miR-277-binding sites were placed in the 3¢-UTR of the reporter mRNA, the miR-277-complementary ASO inhibited miR-277 regulation, increasing expression of the GFP reporter four-to fivefold; the control ASO had no effect. miR-277 directs repression of a reporter with two, fully complementary sites (four-to five-fold) to a greater extent than of a reporter bearing four, imperfectly paired miR-277-binding sites (B30%). For this reason, we recommend perfectly matched reporters for testing ASOs. miR-277 inhibition by our ASOs was nearly complete because the degree of derepression was similar to that observed when Ago2 and Ago1, the core RISC proteins that guide miRNA silencing, were depleted by dsRNA-triggered RNAi 14 .
Using our optimized protocol, we see a uniform shift in the FACS curve when miR-277 is inhibited, indicating that transfection was very efficient (490%) (Figs. 4 and 5) . If transfection is incomplete, two peaks will be observed: one corresponding to cells that received the ASO and the other from those that did not. This is seen if cells are transfected at too high a density (Fig. 5) . Unlike stable GFP cell lines in which fluorescence is measured in every cell, it is more difficult to assess transfection efficiency using the luciferase assay, in which an average from all cells is obtained. In the sequential transfection procedure detailed in Box 1, if ASO treatment derepresses the Renilla luciferase reporter to a level near that of the nontargeted reporter, ASO transfection must have been efficient (i.e., miRNA was inhibited by ASO in all cells that received the reporter). However, if miRNA repression cannot be inhibited by an ASO, low transfection efficiency may be an explanation. Low potency may also be an explanation. This can be tested by cotransfecting the ASO with the reporter instead of sequential transfection; all transfected cells should receive both the reporter and the ASO. If incomplete derepression is still seen, potency may be the problem rather than transfection efficiency. A dose-response curve can be performed to ensure that maximal derepression is being achieved (for sample dose-response curve, see Supplementary Fig. 3a) . Regulation of targets by miRNAs can be quite modest, depending on miRNA and target abundance; twofold regulation or less is not uncommon. Although mRNA abundance is often affected by miRNA regulation, some targets appear to be regulated solely by translational repression 52, 96, 97 . Thus, the absence of a change in mRNA abundance of a putative target is not always meaningful, especially if regulation at the mRNA level has not been previously demonstrated. When possible, measurements of the protein are preferred, as changes in mRNA stability or translation should both affect protein levels. When direct measurement of target protein levels is not feasible, protein level regulation by an miRNA can be assessed using luciferase (Box 1) or GFP reporter assays in which the putative target 3¢-UTR is cloned into the reporter mRNA. In this case, ASO treatment is predicted to increase reporter levels; conversely, increasing miRNA levels should reduce reporter levels.
When specific target seed sequences are suspected, analysis of 3¢-UTRs with mutant seeds can reveal the importance of a specific site for regulation. Such mutational analysis is especially convincing, as it shows that miRNA-target complementarity is required for regulation in the context of a potentially quite large 3¢-UTR. However, the approach assumes that (i) the reporter target expression level is physiologically relevant and (ii) the target and the miRNA are in fact expressed in the same cells. Whenever possible, it is preferable to examine endogenous target mRNA and/or protein levels. Reporter assays are best used to augment analysis and allow more focused studies of 3¢-UTR sequence motifs.
Proving that an miRNA regulates a given target may implicate it in a particular biological pathway, giving a hint at its function. However, with each miRNA having hundreds of putative targets, proving a biological function for any one interaction may be difficult: an individual miRNA's critical function may be modest regulation of hundreds of genes or more substantial regulation of just a few.
Cellular assays
Functional analysis of loss of miRNA function in cultured cells can be performed using any number of cellular assays. Because a growing body of evidence implicates miRNAs in cancer development, maintenance and metastasis, several studies have now employed standard assays for proliferation, apoptosis and metastasis. Using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays and propidium iodide staining coupled with FACS analysis, Matsubara et al. 78 found that blocking miR-20a and miR-17-5p with ASOs reduced cell viability and increased the proportion of sub G1 cells. They also used a TUNEL assay to show increased apoptosis when these same miRNAs are inhibited with ASOs. Similarly, Bommer et al. 75 and colleagues used propidium iodide staining and FACS to show that miR-34 inhibition results in increased viability of colon cancer cells. In parallel, these authors demonstrated that ES cells genetically deleted of all three miR-34 isoforms had essentially the same phenotype as pooled ASO inhibition of miR-34: increased cell viability and increased concentration of anti-apoptotic Bcl2 protein.
Ma et al. 98 found that miR-10b expression enhances metastasis; invasive breast cancer cells failed to migrate as far when treated with miR-10b ASO. ASOs have also been used in xenograft cancer models to demonstrate that some miRNAs affect metastatic potential and in vivo growth of tumors. Whereas Tavazoie et al. 99 found that miR-335 limits breast cancer metastasis (ASO inhibition increases metastasis of xenografted cell lines), Corsten et al. 100 saw that transplanted gliomas treated with miR-21-specific ASO were sensitized to a chemotherapeutic agent.
Several studies use ASOs in conjunction with in vitro differentiation systems to show the importance of individual miRNAs in cellular differentiation. Esau et al. 21 showed that miR-143 expression increases during cultured adipocyte differentiation and that this differentiation is inhibited by an miR-143 ASO. Similarly, Naguibneva et al. 96 showed that miR-181 expression is induced upon myoblast terminal differentiation and that an ASO prevents this differentiation by blocking repression of the miR-181 target mRNA, Hox-A11.
Finally, multiple studies using ASOs suggest roles for endogenous miRNAs in viral defense or replication. Lecellier et al. 56 found that ASO inhibition of miR-32, an miRNA with potential target sites in primate foamy cell virus genes, permits enhanced production of viral RNA in human tissue culture cells. Similarly, inhibition of interferon-b-induced miRNAs permits Hepatitis C viral production 85 . However, ASO inhibition of liver-specific miR-122 in cultured hepatocytes cripples Hepatitis C replication, suggesting its requirement in the Hepatitis C viral life cycle 85, 101 . These ASO studies suggest that combinatorial expression of pro-or antiviral miRNAs may affect tissue tropism of some viruses.
In sum, miRNA function can be efficiently disrupted in cultured mammalian and Drosophila S2 cells. The approaches detailed here should be readily adaptable to study miRNA function in any cell line. 
